WallStreetZenWallStreetZen

NASDAQ: ATXI
Avenue Therapeutics Inc Stock

$0.15+0.00 (+0%)
Updated Mar 27, 2024
ATXI Price
$0.15
Fair Value Price
$0.17
Market Cap
$6.77M
52 Week Low
$0.11
52 Week High
$1.36
P/E
-0.16x
P/B
4.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.38M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.76
Operating Cash Flow
-$9M
Beta
0.6
Next Earnings
Mar 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ATXI Overview

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ATXI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ATXI ($0.15) is undervalued by 9.11% relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ATXI ($0.15) is not significantly undervalued (9.11%) relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ATXI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATXI due diligence checks available for Premium users.

Be the first to know about important ATXI news, forecast changes, insider trades & much more!

ATXI News

Valuation

ATXI fair value

Fair Value of ATXI stock based on Discounted Cash Flow (DCF)
Price
$0.15
Fair Value
$0.17
Undervalued by
10.89%
ATXI ($0.15) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATXI ($0.15) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATXI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ATXI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.16x
Industry
14.3x
Market
44.45x

ATXI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.28x
Industry
6.2x
ATXI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ATXI's financial health

Profit margin

Revenue
$0.0
Net Income
$640.0k
Profit Margin
0%
ATXI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$1.9M
Liabilities
$1.2M
Debt to equity
0.76
ATXI's short-term assets ($1.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATXI's short-term assets ($1.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATXI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATXI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.3M
Investing
$0.0
Financing
$3.9M
ATXI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ATXI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ATXI$6.77M+1.32%-0.16x4.28x
VCNX$6.65M-1.32%-0.09x-1.72x
TRVN$6.96M+3.61%-0.17x1.96x
CELZ$6.99M+1.18%-1.37x0.68x
BRTX$6.56M-0.50%-0.34x0.51x

Avenue Therapeutics Stock FAQ

What is Avenue Therapeutics's quote symbol?

(NASDAQ: ATXI) Avenue Therapeutics trades on the NASDAQ under the ticker symbol ATXI. Avenue Therapeutics stock quotes can also be displayed as NASDAQ: ATXI.

If you're new to stock investing, here's how to buy Avenue Therapeutics stock.

What is the 52 week high and low for Avenue Therapeutics (NASDAQ: ATXI)?

(NASDAQ: ATXI) Avenue Therapeutics's 52-week high was $1.36, and its 52-week low was $0.11. It is currently -88.75% from its 52-week high and 35.4% from its 52-week low.

How much is Avenue Therapeutics stock worth today?

(NASDAQ: ATXI) Avenue Therapeutics currently has 44,260,667 outstanding shares. With Avenue Therapeutics stock trading at $0.15 per share, the total value of Avenue Therapeutics stock (market capitalization) is $6.77M.

Avenue Therapeutics stock was originally listed at a price of $123.74 in Jun 27, 2017. If you had invested in Avenue Therapeutics stock at $123.74, your return over the last 6 years would have been -99.88%, for an annualized return of -67.24% (not including any dividends or dividend reinvestments).

How much is Avenue Therapeutics's stock price per share?

(NASDAQ: ATXI) Avenue Therapeutics stock price per share is $0.15 today (as of Mar 27, 2024).

What is Avenue Therapeutics's Market Cap?

(NASDAQ: ATXI) Avenue Therapeutics's market cap is $6.77M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Avenue Therapeutics's market cap is calculated by multiplying ATXI's current stock price of $0.15 by ATXI's total outstanding shares of 44,260,667.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.